Attached files
| file | filename |
|---|---|
| EX-5.1 - EXHIBIT 5.1 - Cellectar Biosciences, Inc. | tm2020240d1_ex5-1.htm |
| EX-4.4 - EXHIBIT 4.4 - Cellectar Biosciences, Inc. | tm2020240d1_ex4-4.htm |
| EX-4.3 - EXHIBIT 4.3 - Cellectar Biosciences, Inc. | tm2020240d1_ex4-3.htm |
| EX-1.1 - EXHIBIT 1.1 - Cellectar Biosciences, Inc. | tm2020240d1_ex1-1.htm |
| S-1/A - S-1/A - Cellectar Biosciences, Inc. | tm2020240d1_s1a.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the use in this Amended Registration Statement on Form S 1/A of Cellectar Biosciences, Inc. and Subsidiary (the “Company”) of our report dated March 9, 2020, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect to our audit of the consolidated financial statements of Cellectar Biosciences, Inc. and Subsidiary for the years ended December 31, 2019 and 2018 which are incorporated by reference in this Amended Registration Statement. We also consent to the reference to us under the heading “Experts” in such Amended Registration Statement.
Madison,
Wisconsin
May 20, 2020
Baker Tilly Virchow Krause, LLP trading as Baker Tilly is a member of the global network of Baker Tilly International Ltd., the members of which are separate and independent legal entities. © 2018 Baker Tilly Virchow Krause, LLP